Eurobiomed is pleased to invite you to the 3rd edition of Immunology Days, to be held at the EMD in Marseille. Under the theme “ All committed to the development of immune therapies against cancer, inflammatory and infectious diseases ”, this year’s event will bring together key players from research and industry to advance innovations in immunology. This unique event offers a space dedicated to exchanging knowledge and sharing scientific advances in the field of immunology. Participants will be able to attend presentations of innovative projects and discover new perspectives on immune therapies, all in a setting conducive to scientific interaction.
PROGRAM
Welcome - Coffee
Introduction
Pierre d'EPENOUX - Vice-President, Eurobiomed
Words from local authorities
An update : MIB, an International Biocluster in Immunology
Pr Daniel OLIVE - MD PhD, Aix-Marseille Université
Part 1: Ambition to accelerate, target discovery, validation and success
Beacon technology
Name pending - Brucker
Harnessing the potential of CAR-T cell therapy through new cellular engineering
Pr. Bernard MALISSEN
C2IT, When IPC and APHM join forces to reinforce clinical trials in immunology
Pr Norbert VEY - Managing Director, Institut Paoli-Calmettes & Emilie GARRIDO PRADALIE - Directrice Recherche en Santé et Maladies Rares, Assistance Publique - Hôpitaux de Marseille
New strategies to target and eliminate pathogenic B-cells producing auto-antibodies in vasculitis
Pr. Noémie JOURDE-CHICHE
12h20 : Lunch and Networking
Key Note : Sanofi, a global strategy to target immune-diseases,
Frédéric MARRACHE - VP -Global Project Head - Clinical Development - Immunology and Inflammation Therapeutic Area, SANOFI
Part 2: A hub for industrial innovation from discovery to industrialization
Remora Biotech Venture Builder : new generation of first-in class and multifunctional immunotherapy products to treat cancer and AID
Mr David BECHARD- PhD CEO, Remora Biotech France – Nanomunity – Radiomune Pharma
A full service approach to revealed original targets for antibody-based therapy,
François ROMAGNE - Directeur Scientifique, MImAbs
Imcheck Therapeutics
Name to be confirmed
New opportunities for democratizing the use of flow cytometry
Mr Fabrice MALERGUE- PhD Senior Staff Research Scientist, Beckman Coulter Life Sciences/ Immunotech
Networking
End
About MIB
Located at the center of Marseille, home of immunology research for over 40 years, the mission of MIB is to develop and implement cooperation between all stakeholders of tomorrow’s immunology at the national and international levels. Researchers, hospital practitioners, biotechs & pharma innovators, investors, students and public authorities will benefit from a dynamic environment (technology platforms, immunology start-up studios, support for SMEs and larger companies, etc.) and complementary expertise to develop cutting-edge immune-based therapies and new diagnostic tools. With a budget of €97 million as part of the France 2030 Plan, MIB aims to accelerate translational research in immunology, focusing on four therapeutic areas: oncology, infectiology, autoimmune and inflammatory diseases, for the benefit of patients.
MIB partners :
